Werewolf Therapeutics, Inc. (HOWL)
NASDAQ: HOWL · Real-Time Price · USD
1.900
+0.120 (6.74%)
At close: Nov 22, 2024, 4:00 PM
1.970
+0.070 (3.68%)
After-hours: Nov 22, 2024, 6:48 PM EST
Werewolf Therapeutics Revenue
Werewolf Therapeutics had revenue of $3.39M in the twelve months ending September 30, 2024, down -86.84% year-over-year. In the year 2023, Werewolf Therapeutics had annual revenue of $19.94M with 21.60% growth.
Revenue (ttm)
$3.39M
Revenue Growth
-86.84%
P/S Ratio
23.21
Revenue / Employee
$72,043
Employees
47
Market Cap
84.67M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 19.94M | 3.54M | 21.60% |
Dec 31, 2022 | 16.40M | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
MDxHealth | 84.71M |
CervoMed | 10.07M |
WORK Medical Technology Group LTD | 9.86M |
Armata Pharmaceuticals | 5.47M |
Ikena Oncology | 659.00K |
Chimerix | 159.00K |
Genelux | 8.00K |
HOWL News
- 3 days ago - Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference - GlobeNewsWire
- 16 days ago - Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting - GlobeNewsWire
- 7 weeks ago - Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer's (SITC) 39th Annual Meeting - GlobeNewsWire
- 3 months ago - Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - GlobeNewsWire
- 5 months ago - Werewolf Therapeutics: Continuing To Advance And Show More Promise In Phase 1 - Seeking Alpha
- 5 months ago - Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma - GlobeNewsWire
- 6 months ago - Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors - GlobeNewsWire
- 6 months ago - Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference - GlobeNewsWire